Nanexa AB

NANEXA · Nasdaq Stockholm · Healthcare

9.99SEK +0.3%last day

Price as of 2 October 2026

The price over the past year, with dividends: +350.0%

Performance

1 month

+71.6%

1 year

+350.0%

3 years, per year

+116.2%

5 years, per year

+19.6%

Largest fall, 3 years

−95.2%

Below the peak now

−29.4%

Volatility, 1 year

131.2%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

13.7

Dividend yield

0.0%

Return on equity

−18.5%

Net margin

−72.5%

Market value

187 m USD

Quality, value and trend

Where Nanexa stands against every Nordic stock today. 100 is best.

Quality62

Profitability and a sound balance sheet over time. Better than 62% of Nordic stocks.

Value5

The price measured against earnings, assets and cash flow. Better than 5% of Nordic stocks.

Trend100

The price development over the past year. Better than 100% of Nordic stocks.

Combined57

Quality, value and trend together. Better than 57% of Nordic stocks.

About Nanexa

Nanexa AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 17 employees.

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis